BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| JEFFREY LAST New | LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08 |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| JEFFREY LAST New | LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08 |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
| JEFFREY LAST New | LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08 |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.